Bimatoprost
- Generic Name
- Bimatoprost
- Brand Names
- Durysta, Latisse, Lumigan
- Drug Type
- Small Molecule
- Chemical Formula
- C25H37NO4
- CAS Number
- 155206-00-1
- Unique Ingredient Identifier
- QXS94885MZ
- Background
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertensio...
- Indication
Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.
Bimatoprost is also indicated to treat eyelash hypotrichosis.
- Associated Conditions
- Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)
- Associated Therapies
- -
An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
- Conditions
- Interventions
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- ForSight Vision5, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT02143843
- Locations
- 🇺🇸
Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Sall Medical Research Center, Artesia, California, United States
🇺🇸Coastal Research Associates, Atlanta, Georgia, United States
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
- Conditions
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Cardiff University
- Target Recruit Count
- 31
- Registration Number
- NCT02059655
- Locations
- 🇬🇧
University Hospital of Wales, Cardiff, United Kingdom
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2013-08-05
- Last Posted Date
- 2018-04-20
- Lead Sponsor
- ForSight Vision5, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT01915940
- Locations
- 🇺🇸
Ophthalmology Associates PC, Fort Worth, Texas, United States
🇺🇸UNC Kittner Eye Center, Chapel Hill, North Carolina, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- University of Parma
- Target Recruit Count
- 61
- Registration Number
- NCT01655758
- Locations
- 🇮🇹
University Eye Clinic, Parma, Italy
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- Allergan
- Target Recruit Count
- 2580
- Registration Number
- NCT01646151
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Allergan
- Target Recruit Count
- 125
- Registration Number
- NCT01291108
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
- Conditions
- Interventions
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Summa Health System
- Target Recruit Count
- 89
- Registration Number
- NCT00705757
- Locations
- 🇺🇸
Arlington Eye Physicians, Arlington Heights, Illinois, United States
🇺🇸Summa Health System, Akron, Ohio, United States
A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension
- Conditions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2007-06-01
- Lead Sponsor
- Innovative Medical
- Registration Number
- NCT00348062
- Locations
- 🇺🇸
Dr. Noecker, Pittsburgh, Pennsylvania, United States
Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
- Conditions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2011-05-30
- Lead Sponsor
- Allergan
- Target Recruit Count
- 561
- Registration Number
- NCT00300443
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.